Skip to Content

Biomarin Pharmaceutical Inc BMRN

Morningstar Rating
$87.14 +0.86 (1.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

BioMarin Earnings: In-Line 2023 Results; Maintaining FVE Despite Lowering Our 2024 Forecast

BioMarin saw 20% year-over-year revenue growth in the fourth quarter as achondroplasia drug Voxzogo continued its strong trajectory, and we're maintaining our $96 fair value estimate. We think BioMarin shares are fairly valued at recent prices, incorporating both Voxzogo's strong potential and BioMarin's improving overall operating margins, but also a disappointing launch for hemophilia A gene therapy Roctavian and unclear potential for the firm's pipeline. We continue to see BioMarin's portfolio and pipeline of rare disease drugs supporting a narrow moat.

Price vs Fair Value

BMRN is trading at a 9% discount.
Price
$87.14
Fair Value
$46.00
Uncertainty
High
1-Star Price
$757.10
5-Star Price
$91.40
Economic Moat
Ryjmmj
Capital Allocation
Rcfnlxbs

Bulls Say, Bears Say

Bulls

BioMarin's approved drugs have been granted orphan-drug status in the US and EU, providing them with at least 7 and 10 years of market exclusivity, respectively.

Bears

Diagnosis of rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing costs.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BMRN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$86.28
Day Range
$85.8888.28
52-Week Range
$76.02101.48
Bid/Ask
$84.93 / $88.60
Market Cap
$16.44 Bil
Volume/Avg
1.9 Mil / 1.6 Mil

Key Statistics

Price/Earnings (Normalized)
105.01
Price/Sales
6.90
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
3,401

Competitors

Valuation

Metric
BMRN
PFE
SNY
Price/Earnings (Normalized)
105.0114.459.95
Price/Book Value
3.311.691.55
Price/Sales
6.902.572.36
Price/Cash Flow
33.6713.8011.57
Price/Earnings
BMRN
PFE
SNY

Financial Strength

Metric
BMRN
PFE
SNY
Quick Ratio
1.450.580.83
Current Ratio
2.510.911.27
Interest Coverage
8.780.7411.03
Quick Ratio
BMRN
PFE
SNY

Profitability

Metric
BMRN
PFE
SNY
Return on Assets (Normalized)
6.15%4.98%8.05%
Return on Equity (Normalized)
8.47%10.90%14.38%
Return on Invested Capital (Normalized)
6.27%7.28%10.85%
Return on Assets
BMRN
PFE
SNY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJgq$550.4 Bil
VRTX
Vertex Pharmaceuticals IncVlfqqv$111.8 Bil
REGN
Regeneron Pharmaceuticals IncTknxgb$107.9 Bil
MRNA
Moderna IncNpsx$36.3 Bil
ARGX
argenx SE ADRFfp$23.0 Bil
BNTX
BioNTech SE ADRPmt$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncRxxtq$19.2 Bil
RPRX
Royalty Pharma PLC Class AJtzrpx$13.4 Bil
INCY
Incyte CorpWpspj$13.3 Bil

Sponsor Center